Richard Visit 1: A 54-year-old Caucasian male with type 2 diabetes, dyslipidemia, and hypertension
| Title: | Richard Visit 1: A 54-year-old Caucasian male with type 2 diabetes, dyslipidemia, and hypertension |
| Topic: | Diabetology |
| Relevant Terms: | Diabetes, Dyslipidemia, Hypertension, Insulin Resistance, Metabolic Syndrome |
| Primary Audience: | Primary care providers and other healthcare professionals who treat adults with diabetes |
| Launch Date: | 01-Feb-10 |
| Credits: | 0.5 AMA PRA Category 1 Credit™ |
| Expiration Date: | 31-Dec-12 |
Learning Objectives
Upon completion of the activity, participants should be able to:
- Explain the natural history of type 2 diabetes including evolution of insulin resistance, insulin secretory decline, derangements in incretin system, and endocrinologic role of abdominal adiposity as key components of clinical progression of disease
- Describe the pathophysiologic and clinical interrelationships between type 2 diabetes and risk factors for, and consequences of, cardiometabolic syndrome
- Assess underlying pathophysiologic factors contributing to hyperglycemia of type 2 diabetes based on an individualized clinical assessment of patients with type 2 diabetes
- Advance individualized nonpharmacologic and pharmacotherapeutic treatments for type 2 diabetes that address underlying pathophysiology
- Improve office-based systems to manage treatment and facilitate therapeutic advancement, as well as provide patients with educational support to actively participate in their care
Faculty
Planning Committee:
Julie Brown
Director
Professional Education
Joslin Diabetes Center
Boston, MA
James Neighbours, MEd
Assistant Director, Education Technology Services
Professional Education
Joslin Diabetes Center
Boston, MA
DISCLOSURE POLICY STATEMENT
As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center, Boston, must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services with the exception of nonprofit or government organizations and non–healthcare-related companies, which are exempt.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.
If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of the Joslin Diabetes Center.
Dr. Sheehan has received grant/research support, is on the speakers' bureau, and is a consultant for sanofi-aventis U.S. LLC; is on the speakers' bureau and a consultant for Abbott Laboratories, Amylin Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline, NovartisPharmaceuticals Corporation, Novo Nordisk Inc., and Takeda Pharmaceuticals North America, Inc; and is on the speakers' bureau for Pfizer Inc.
Ms. Ghiloni is on the CDE Advisory Board of Agamatrix, Inc. and Can-Am Care, LLC and is a stockholder in Medtronics Corporation and Insulet Corporation.
Dr. Hamdy is on the speaker's bureau for Amylin Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc, sanofi-aventis U.S. LLC and Takeda Pharmaceuticals North America, Inc.
Dr. Beaser is on the academic advisory board for AstraZeneca Pharmaceuticals LP and Bristol-Myers Squibb Company.
Ms. Brown has no relevant financial relationships.
Mr. Neighbours has no relevant financial relationships.
ACCREDITATION STATEMENT
The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION
Joslin Diabetes Center designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To Obtain CME Credits
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the post-test and activity evaluation.
• Physicians who successfully complete the post-test and evaluation will receive CME credit.
• You must score with a 60% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
Release Date: February 1, 2010
Expiration Date: December 31, 2012
ACKNOWLEDGEMENT
This activity is sponsored by Joslin Diabetes Center.

This activity is supported by an educational grant from Merck & Co., Inc.
If you have any questions regarding this activity, send an email to profedweb@joslin.harvard.edu.
Copyright © 2010 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Joslin Diabetes Center is prohibited.
Richard S. Beaser, MD
Associate Clinical Professor of Medicine
Harvard Medical School
Medical Executive Director
Professional Education
Joslin Diabetes Center
Boston, MA
Julie Brown
Director
Professional Education
Joslin Diabetes Center
Boston, MA
James Neighbours, MEd
Assistant Director, Education Technology Services
Professional Education
Joslin Diabetes Center
Boston, MA
DISCLOSURE POLICY STATEMENT
As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center, Boston, must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services with the exception of nonprofit or government organizations and non–healthcare-related companies, which are exempt.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.
If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of the Joslin Diabetes Center.
Dr. Sheehan has received grant/research support, is on the speakers' bureau, and is a consultant for sanofi-aventis U.S. LLC; is on the speakers' bureau and a consultant for Abbott Laboratories, Amylin Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline, NovartisPharmaceuticals Corporation, Novo Nordisk Inc., and Takeda Pharmaceuticals North America, Inc; and is on the speakers' bureau for Pfizer Inc.
Ms. Ghiloni is on the CDE Advisory Board of Agamatrix, Inc. and Can-Am Care, LLC and is a stockholder in Medtronics Corporation and Insulet Corporation.
Dr. Hamdy is on the speaker's bureau for Amylin Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc, sanofi-aventis U.S. LLC and Takeda Pharmaceuticals North America, Inc.
Dr. Beaser is on the academic advisory board for AstraZeneca Pharmaceuticals LP and Bristol-Myers Squibb Company.
Ms. Brown has no relevant financial relationships.
Mr. Neighbours has no relevant financial relationships.
ACCREDITATION STATEMENT
The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION
Joslin Diabetes Center designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To Obtain CME Credits
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the post-test and activity evaluation.
• Physicians who successfully complete the post-test and evaluation will receive CME credit.
• You must score with a 60% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
| PC Internet Explorer (v6 or greater), or Firefox |
MAC Safari |
Release Date: February 1, 2010
Expiration Date: December 31, 2012
ACKNOWLEDGEMENT
This activity is sponsored by Joslin Diabetes Center.
This activity is supported by an educational grant from Merck & Co., Inc.
If you have any questions regarding this activity, send an email to profedweb@joslin.harvard.edu.
Copyright © 2010 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Joslin Diabetes Center is prohibited.







